Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Heather Ogana"'
Autor:
Eitan Kugler, Shreyas Madiwale, Darren Yong, Julie A. I. Thoms, Yehudit Birger, David B. Sykes, Johannes Schmoellerl, Aneta Drakul, Valdemar Priebe, Muhammad Yassin, Nasma Aqaqe, Avigail Rein, Hila Fishman, Ifat Geron, Chun-Wei Chen, Brian Raught, Qiao Liu, Heather Ogana, Elisabeth Liedke, Jean-Pierre Bourquin, Johannes Zuber, Michael Milyavsky, John Pimanda, Gilbert G. Privé, Shai Izraeli
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-20 (2023)
Abstract The ERG (ETS-related gene) transcription factor is linked to various types of cancer, including leukemia. However, the specific ERG domains and co-factors contributing to leukemogenesis are poorly understood. Drug targeting a transcription f
Externí odkaz:
https://doaj.org/article/d7035b0bdc8b4304be06aaa591c4d83a
Autor:
Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew A. Boudreau, Benjamin Buelow, Kevin Dang, Laura M. Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim Van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein, Udaya S. Rangaswamy
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents,
Externí odkaz:
https://doaj.org/article/54c6dadc1dc04e3c82d81639cfba9a39
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
The interaction between leukemia cells and the bone microenvironment is known to provide drug resistance in leukemia cells. This phenomenon, called cell adhesion-mediated drug resistance (CAM-DR), has been demonstrated in many subsets of leukemia inc
Externí odkaz:
https://doaj.org/article/e6811e507dc94279b2d73d2e886a9252
Autor:
Hsiao-Chuan Liu, Eun Ji Gang, Hye Na Kim, Yongsheng Ruan, Heather Ogana, Zesheng Wan, Halvard Bönig, K. Kirk Shung, Yong-Mi Kim
Publikováno v:
Cells, Vol 9, Iss 6, p 1470 (2020)
Drug resistance is an obstacle in the therapy of acute lymphoblastic leukemia (ALL). Whether the physical properties such as the motility of the cells contribute to the survival of ALL cells after drug treatment has recently been of increasing intere
Externí odkaz:
https://doaj.org/article/30672be8be56480c9375232af11d1257
Publikováno v:
Curr Top Microbiol Immunol
Current Topics in Microbiology and Immunology ISBN: 9783031065651
Current Topics in Microbiology and Immunology ISBN: 9783031065651
Despite the therapeutic progress, relapse remains a major problem in the treatment of acute lymphoblastic leukemia (ALL). Most leukemia cells that survive chemotherapy are found in the bone marrow (BM), thus resistance to chemotherapy and other treat
Autor:
Heather Ogana, Samantha Hurwitz, Zesheng Wan, Hye Na Kim, Samy Jambon, Hisham Abdel-Azim, Miller Huang, Moghimi Babak, Nora Heisterkamp, Anne-Marie Carbonell, Chintan Parekh, Marina Konopleva, Deepa Bhojwani, Yong-Mi Kim
Publikováno v:
Blood. 140:8799-8800
Autor:
Hsiao-Chuan Liu, Mo Yang, Deepa Bhojwani, Hye Na Kim, Heather Ogana, Shuangyue Li, Alan S. Wayne, Yongsheng Ruan, Eun Ji Gang, Yong-Mi Kim
Publikováno v:
Experimental and Therapeutic Medicine
Treatment of resistant or recurrent acute lymphoblastic leukemia (ALL) remains a challenge. It was previously demonstrated that the adhesion molecule integrin α4, referred to hereafter as α4, mediates the cell adhesion-mediated drug resistance (CAM
Publikováno v:
Blood. 140:5995-5995
Autor:
Suhasini Iyer, Roland Buelow, Udaya Rangaswamy, Harbani K. Malik-Chaudhry, Kevin Dang, Katherine E. Harris, Duy Pham, Nathan D. Trinklein, Benjamin Buelow, Andrew Boudreau, Harshad Ugamraj, Brett Jorgensen, Wim Van Schooten, Heather Ogana, Laura Davison, Ute Schellenberger, Kirthana Prabhakar
Publikováno v:
mAbs
article-version (VoR) Version of Record
article-version (VoR) Version of Record
The therapeutic potential of targeting CD19 in B cell malignancies has garnered attention in the past decade, resulting in the introduction of novel immunotherapy agents. Encouraging clinical data have been reported for T cell-based targeting agents,
Autor:
Daniel Bsteh, Shivani Soni, Heather Ogana, Heinz-Josef Lenz, Stephen V. Frye, Stephanie H. Cholensky, Justin M. Rectenwald, Yibo Si, Oliver Bell, Jacqueline L. Norris, Junghyun L. Suh, Lindsey I. James, Tyler M. Weaver, Jessica D. Umana, Dmitri Kireev, Yong-Mi Kim, Bryce Hart, Shannon M. Mumenthaler, Brian Hardy, Cari A. Sagum, Catherine A. Musselman, Roy Lau, Gang Greg Wang, Dongxu Li, Ken H. Pearce, Mark T. Bedford, Carina Pribitzer
Canonical targeting of Polycomb Repressive Complex 1 (PRC1) to repress developmental genes is mediated by cell type-specific, paralogous chromobox (CBX) proteins (CBX2, 4, 6, 7 and 8). Based on their central role in silencing and their misregulation
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::041c17c959746d5da4e46faee689c326
https://doi.org/10.1101/2021.02.23.432388
https://doi.org/10.1101/2021.02.23.432388